Kang Yongbo, Pan Wei, Cai Yue
Medical Faculty, Kunming University of Science and Technology, Kunming, Yunnan, China.
Genetics and Pharmacogenomics Laboratory, Kunming University of Science and Technology, Kunming, Yunnan, China.
Z Gastroenterol. 2017 Sep;55(9):872-880. doi: 10.1055/s-0043-116387. Epub 2017 Sep 12.
Colorectal cancer (CRC), as a leading cause of cancer-related death, is triggered by the complex interplay of host genetics and environmental factors. Mounting evidence has shed light on the association of the gut microbiota dysbiosis with CRC. In CRC experimental models, certain gut microbial strains have been shown to inhibit or attenuate immune responses, indicating that specific species among intestinal commensal bacteria may play either a pathogenic or a protective role in the development of CRC. Oral intake of probiotics/prebiotics can therefore serve as a therapeutic approach for CRC treatment. Microbiota studies in cancer, however, are still at the early stage, lack of quantitative data for clinic application. Fortunately, sequencing-based technologies are a boon to further investigation on the association of the intestinal bacterial flora and human diseases. This review considers the evidence for the role of the gut microbiota in CRC development and progression, responsiveness to immune system, and the related therapeutic applications of probiotics/prebiotics.
结直肠癌（CRC）作为癌症相关死亡的主要原因，是由宿主基因与环境因素的复杂相互作用引发的。越来越多的证据揭示了肠道微生物群失调与CRC之间的关联。在CRC实验模型中，某些肠道微生物菌株已被证明可抑制或减弱免疫反应，这表明肠道共生细菌中的特定物种可能在CRC的发展中发挥致病或保护作用。因此，口服益生菌/益生元可作为CRC治疗的一种方法。然而，癌症中的微生物群研究仍处于早期阶段，缺乏临床应用的定量数据。幸运的是，基于测序的技术有助于进一步研究肠道细菌菌群与人类疾病的关联。本综述探讨了肠道微生物群在CRC发展和进展中的作用、对免疫系统的反应以及益生菌/益生元的相关治疗应用的证据。
